Live
Glenmark Pharmaceuticals has launched ‘Digihaler’, which will be the country’s first digital dose inhaler (DDI), for asthma and chronic obstructive pulmonary disease patients.
The firm has said in a statement that “This next-gen inhaler provides accurate digital dose counter along with low dose warning indicator to enable Asthma and chronic obstructive pulmonary disease patients to track adherence to their therapy.”
Sujesh Vasudevan, Glenmark Pharmaceuticals President and Head of India Formulations and Africa Region, said that “The device (Digihaler) will enable the patients to track the number of doses that have been consumed and prominently placed indicator provides a low dose warning which is beneficial to patients. This will further enable the doctors to determine patient’s adherence to the prescribed therapy regime.”
